Immupharma PLC Admission today to trading on Euronext Growth (2964X)
19 Diciembre 2019 - 1:00AM
UK Regulatory
TIDMIMM
RNS Number : 2964X
Immupharma PLC
19 December 2019
RNS | 19 December 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
Admission today to trading on Euronext Growth Brussels
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), a specialist
drug discovery and development company, is pleased to announce
that, this morning at approximately 09.00am (GMT), ImmuPharma will
commence trading on Euronext Growth Brussels ("Euronext") under
ticker 'ALIMM'.
This new listing does not affect the trading of ImmuPharma's
shares on AIM, nor is there any intention from the Company to raise
additional funds from either AIM or Euronext.
The dual listing on Euronext Growth Brussels aims to further
increase the visibility of ImmuPharma's shares with European
investors, aligned with the investment thesis for ImmuPharma and
specifically Lupuzor(TM) being repositioned, following the
Company's recent deal with US Avion Pharmaceuticals, who are
funding an international Phase III trial for ImmuPharma's lead
programme, Lupuzor(TM). ImmuPharma looks forward to providing
further progress updates on the Phase III program with Avion, as
well as entering into additional partnerships outside of the
US.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 747 02 60 +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784 +32 (0) 477 504 784
Jean-Louis Dubrule +32 (0) 497 50 84 03 +32 (0) 497 50 84 03
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases
and cancer. The lead program, LupuzorTM, is a first-in class
autophagy immunomodulator which is in Phase III for the treatment
of lupus and preclinical analysis suggest therapeutic activity for
many other autoimmune diseases that share the same autophagy
mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
29 November 2019, an exclusive licence and development agreement
and trademark agreement for Lupuzor(TM) to fund a new international
Phase III trial for Lupuzor(TM) and commercialise in the US. For
additional information about ImmuPharma please visit
www.immupharma.com.
About Avion Pharmaceuticals
Avion Pharmaceuticals, LLC is a US-based specialty
pharmaceutical company formed to develop, acquire and market a
portfolio of innovative pharmaceutical products in the Women's
Health and other therapeutic categories aligned with our mission to
improve the quality of patient lives. Avion Pharmaceuticals focuses
on identifying opportunities to develop, acquire and enhance the
market potential of innovative, commercially available therapeutics
and late-stage development drugs to fulfil unmet medical needs. For
additional information about Avion Pharmaceuticals, visit
www.avionrx.com.
About Lupuzor(TM) and Lupus
Lupuzor(TM) is ImmuPharma's lead compound, a peptide therapeutic
and a first-in class autophagy immunomodulator for systemic lupus
erythematosus (SLE or lupus) a potentially life-threatening
auto-immune disease. Lupus is a chronic inflammatory disease which
is thought to affect some 5 million individuals worldwide. The
current standard of care still consists of drugs which have many
side-effects and limited efficacy. Despite the need for an
effective treatment, only one new therapy, namely GlaxoSmithKline's
Benlysta, has been approved to treat the condition over the past 50
years. As such, there clearly exists an unmet medical need for a
drug that has a strong efficacy and safety profile.
About Euronext
Euronext is the leading pan-European exchange, covering Belgium,
France, Ireland, The Netherlands, Norway, Portugal and the UK. With
close to 1,500 listed issuers worth EUR4.3 trillion in market
capitalisation as of end September 2019, Euronext has an unmatched
blue chip franchise that includes 26 issuers in the Morningstar(R)
Eurozone 50 IndexSM and a strong diverse domestic and international
client base. Euronext operates regulated and transparent equity and
derivatives markets and is the largest centre for debt and funds
listings in the world. Its total product offering includes
Equities, FX, Exchange Traded Funds, Warrants & Certificates,
Bonds, Derivatives, Commodities and Indices. Euronext also
leverages its expertise in running markets by providing technology
and managed services to third parties. In addition to its main
regulated market, Euronext also operates Euronext GrowthTM and
Euronext AccessTM, simplifying access to listing for SMEs. The
Norwegian stock exchange and its clearing & settlement
subsidiary, together operating as Oslo Børs VPS, joined Euronext on
17 June 2019.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEANAPFESNFEF
(END) Dow Jones Newswires
December 19, 2019 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
